These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25790347)

  • 21. Topical sirolimus for the treatment of angiofibromas in tuberous sclerosis.
    Cinar SL; Kartal D; Bayram AK; Canpolat M; Borlu M; Ferahbas A; Per H
    Indian J Dermatol Venereol Leprol; 2017; 83(1):27-32. PubMed ID: 27643542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity.
    Wataya-Kaneda M; Tanaka M; Nakamura A; Matsumoto S; Katayama I
    Br J Dermatol; 2011 Oct; 165(4):912-6. PubMed ID: 21692771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex.
    Lee YI; Lee JH; Kim DY; Chung KY; Shin JU
    Dermatology; 2018; 234(1-2):13-22. PubMed ID: 29925060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.
    Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H;
    JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tuberous Sclerosis Complex in 29 Children: Clinical and Genetic Analysis and Facial Angiofibroma Responses to Topical Sirolimus.
    Wang S; Liu Y; Wei J; Zhang J; Wang Z; Xu Z
    Pediatr Dermatol; 2017 Sep; 34(5):572-577. PubMed ID: 28771801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of angiofibromas in tuberous sclerosis complex: the effect of topical rapamycin and concomitant laser therapy.
    Park J; Yun SK; Cho YS; Song KH; Kim HU
    Dermatology; 2014; 228(1):37-41. PubMed ID: 24401865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new rapamycin cream formulation improves facial angiofibromas.
    Br J Dermatol; 2023 Oct; 189(5):e89. PubMed ID: 37879746
    [No Abstract]   [Full Text] [Related]  

  • 28. Long-term stability of 0.1% rapamycin hydrophilic gel in the treatment of facial angiofibromas.
    Le Guyader G; Vieillard V; Andrieux K; Rollo M; Thirion O; Wolkenstein P; Paul M
    Eur J Hosp Pharm; 2020 Mar; 27(e1):e48-e52. PubMed ID: 32296505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topical use of mammalian target of rapamycin inhibitors in dermatology: A systematic review with meta-analysis.
    Leducq S; Giraudeau B; Tavernier E; Maruani A
    J Am Acad Dermatol; 2019 Mar; 80(3):735-742. PubMed ID: 30744877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Facial angiofibromas treated by rapamycin 0.05% ointment and a combined laser therapy.
    Negosanti F; Tengattini V; Gurioli C; Neri I
    J Cosmet Dermatol; 2018 Oct; 17(5):762-765. PubMed ID: 30123982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin.
    Koenig MK; Hebert AA; Roberson J; Samuels J; Slopis J; Woerner A; Northrup H
    Drugs R D; 2012 Sep; 12(3):121-6. PubMed ID: 22934754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Facial Angiofibroma Severity Index (FASI): reliability assessment of a new tool developed to measure severity and responsiveness to therapy in tuberous sclerosis-associated facial angiofibroma.
    Salido-Vallejo R; Ruano J; Garnacho-Saucedo G; Godoy-Gijón E; Llorca D; Gómez-Fernández C; Moreno-Giménez JC
    Clin Exp Dermatol; 2014 Dec; 39(8):888-93. PubMed ID: 25142297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective study of rapamycin or rapalog 0·1% cream for facial angiofibromas in tuberous sclerosis complex: evaluation of treatment effectiveness and cost.
    Norrenberg S; Masconi M; Karamanou M; Meylan P; Golaz R; Christen-Zaech S
    Br J Dermatol; 2018 Jul; 179(1):208-209. PubMed ID: 29380350
    [No Abstract]   [Full Text] [Related]  

  • 34. Topical mTOR (mechanistic target of rapamycin) inhibitor therapy in facial angiofibroma.
    Samanta D
    Indian J Dermatol Venereol Leprol; 2015; 81(5):540-1. PubMed ID: 26323682
    [No Abstract]   [Full Text] [Related]  

  • 35. Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.
    Wataya-Kaneda M; Ohno Y; Fujita Y; Yokozeki H; Niizeki H; Ogai M; Fukai K; Nagai H; Yoshida Y; Hamada I; Hio T; Shimizu K; Murota H
    JAMA Dermatol; 2018 Jul; 154(7):781-788. PubMed ID: 29800026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy and safety of topical rapamycin-calcitriol for facial angiofibromas in patients with tuberous sclerosis complex: a prospective, double-blind, randomized clinical trial.
    Chen PL; Hong JB; Shen LJ; Chen YT; Wang SJ; Liao YH
    Br J Dermatol; 2020 Oct; 183(4):655-663. PubMed ID: 32064596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Formulation and characterization of a 0.1% rapamycin cream for the treatment of Tuberous Sclerosis Complex-related angiofibromas.
    Bouguéon G; Lagarce F; Martin L; Pailhoriès H; Bastiat G; Vrignaud S
    Int J Pharm; 2016 Jul; 509(1-2):279-284. PubMed ID: 27260135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined treatment of disfiguring facial angiofibromas in tuberous sclerosis complex with surgical debulking and topical sirolimus.
    Patterson JL; Iyengar S; Catasus C; Kolodney JA; Zinn Z
    Cutis; 2020 Dec; 106(6):307-308. PubMed ID: 33471874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.
    Wataya-Kaneda M; Tanaka M; Yang L; Yang F; Tsuruta D; Nakamura A; Matsumoto S; Hamasaki T; Tanemura A; Katayama I
    JAMA Dermatol; 2015 Jul; 151(7):722-30. PubMed ID: 25692384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex.
    Hamada I; Yukutake Y; Morita Y; Ishikawa N; Shimizu K; Wataya-Kaneda M
    J Dermatol; 2024 Jun; 51(6):752-758. PubMed ID: 38619178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.